Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy - Kerstin Pfister; Thomas W. P. Friedl; Andreas Hartkopf; Franziska Mergel; Sophia Huesmann; Forca Mehmeti; Henning Schäffler; Angelina Fink; Tatjana Braun; Sabine Heublein; Lisa Wiesmüller; Klaus Pantel; et al. (PLoS ONE, 2025)